Over the past four years, the European life sciences real estate sector has solidified its position as a thriving and dynamic market. By examining the data and trends from 2021 to 2024, we uncover how life sciences real estate has attracted a diverse array of investors—from global institutional giants to nimble boutique firms—while evolving into one of the most specialised and technically demanding asset classes.
Investment
€8.4 billion and counting: four years of life sciences real estate deals in Europe
We reflect on the trends and milestones from 2021 to 2024 and explore the drivers behind the sector's growth, the key investment strategies, and the insights that have shaped its trajectory.
6 min read
Table of Contents
Written by
More from Life Sciences Real Estate
paid
The overlooked similarities between life sciences facilities and data centres
As AI reshapes both biotech and cloud computing, investors are increasingly drawn to these surprisingly similar asset classes.
5 min read
paid
The global real estate leaders' playbook for European life sciences
Leading real estate investment managers have shown substantial interest in Europe's life sciences sector.
4 min read
paid
Why institutional real estate investors are turning to medtech
Real estate investors like having medtech companies as tenants.
8 min read